Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020331 · ClinicalTrials.gov registry record · Phase 2
Memantine Therapy in Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by Phoenix Neurological Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01020331: Completed Phase 2 study, sponsored by Phoenix Neurological Associates.
NCT01020331 is a Phase 2 study that has completed, run by Phoenix Neurological Associates. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020331, a Phase 2 study, has completed, sponsored by Phoenix Neurological Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hyperphosphorylation of Tau and therefore the investigators are looking at the efficacy of Memantine at 10 mg twice a day (BID) to see if disease progression correlates with possible changes in Tau in ALS patients based on ALS Functional Rating Scale (ALSFRS) scores.
Interventions
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT01020331 record still lists
NCT01020331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Memantine is the first listed.
NCT01020331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01020331 about?
NCT01020331 is a clinical study titled "Memantine Therapy in Amyotrophic Lateral Sclerosis". Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hy...
What is the current status of trial NCT01020331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT01020331?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT01020331?
This trial is sponsored by Phoenix Neurological Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01020331's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia